##  [Strategic Consulting for Early Approval of Medicinal Products in Japan: Utilizing Foreign Clinical Data and PMDA Consultation](/white-papers/strategic-consulting-for-early-approval-of-medicinal-products-in-japan-utilizing-foreign-clinical-data-and-pmda-consultation) 

- [Medicinal Products](/white-papers-categories/medicinal-products)
- [Regulatory Affairs](/white-papers-categories/regulatory-affairs)





 ![Strategic Consulting for Early Approval of Medicinal Products in Japan: Utilizing Foreign Clinical Data and PMDA Consultation]()

When a foreign pharmaceutical company conducts clinical trials in the Japanese population in Japan to obtain approval for a medicinal product from the Health Authority in Japan, MHLW (Ministry of Health, Labor and Welfare) a clinical development strategy is required to obtain Japanese data for J-NDA filing for the following cases.



Fill the form below to download the White Paper

 You must have JavaScript enabled to use this form.

  

  

  

 How did you hear about us?Search EngineE-mail CampaignGoogle AdsSocial MediaLink from another websiteColleague’s RecommendationNewsletterPrinted BrochureOther 

  

 

 

     I have read the [privacy policy](https://www.freyrsolutions.com/privacy-policy) 



 

 Submitted Page URL  

 Website URL  

 Content Type  

 Form Name